7TB4

Cryo-EM structure of the spike of SARS-CoV-2 Omicron variant of concern

Summary for 7TB4

• Entry DOI: 10.2210/pdb7tb4/pdb
• EMDB information: 25792
• Descriptor: Surface glycoprotein, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose (3 entities in total)
• Functional Keywords: sars-cov-2, spike, omicron, variant of concern, viral protein
• Biological source: Severe acute respiratory syndrome coronavirus 2
• Total number of polymer chains: 3
• Total formula weight: 410176.33

Authors

Zhou, T.,Tsybovsky, T.,Kwong, P.D. (deposition date: 2021-12-21, release date: 2022-01-12, Last modification date: 2024-10-23)

Primary citation

Wang, L.,Zhou, T.,Zhang, Y.,Yang, E.S.,Schramm, C.A.,Shi, W.,Pegu, A.,Oloninyi, O.K.,Ransier, A.,Darko, S.,Narpala, S.R.,Hatcher, C.,Martinez, D.R.,Tsybovsky, Y.,Phung, E.,Abiona, O.M.,Cale, E.M.,Chang, L.A.,Corbett, K.S.,DiPiazza, A.T.,Gordon, I.J.,Leung, K.,Liu, T.,Mason, R.D.,Nazzari, A.,Novik, L.,Olia, A.S.,Doria-Rose, N.A.,Stephens, T.,Stringham, C.D.,Talana, C.A.,Teng, I.T.,Wagner, D.,Widge, A.T.,Zhang, B.,Roederer, M.,Ledgerwood, J.E.,Ruckwardt, T.J.,Gaudinski, M.R.,Baric, R.S.,Graham, B.S.,McDermott, A.B.,Douek, D.C.,Kwong, P.D.,Mascola, J.R.,Sullivan, N.J.,Misasi, J.
Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants.
Biorxiv, 2021

PubMed Abstract: The emergence of highly transmissible SARS-CoV-2 variants of concern (VOC) that are resistant to therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies. We identify four receptor-binding domain targeting antibodies from three early-outbreak convalescent donors with potent neutralizing activity against 12 variants including the B.1.1.7 and B.1.351 VOCs. Two of them are ultrapotent, with sub-nanomolar neutralization titers (IC50 <0.0006 to 0.0102 μ g/mL; IC80 < 0.0006 to 0.0251 μ g/mL). We define the structural and functional determinants of binding for all four VOC-targeting antibodies, and show that combinations of two antibodies decrease the in vitro generation of escape mutants, suggesting potential means to mitigate resistance development. These results define the basis of therapeutic cocktails against VOCs and suggest that targeted boosting of existing immunity may increase vaccine breadth against VOCs.

PubMed: 33655252
DOI: 10.1101/2021.02.25.432969

Experimental method

ELECTRON MICROSCOPY (3.29 Å)